Land: Singapur
Sprache: Englisch
Quelle: HSA (Health Sciences Authority)
Insulin aspart
NOVO NORDISK PHARMA (SINGAPORE) PTE LTD
A10AB05
100 u/ml
INJECTION
Insulin aspart 100 u/ml
INTRAVENOUS, SUBCUTANEOUS
Prescription Only
Novo Nordisk A/S
ACTIVE
2000-09-12
1 NOVORAPID ® PENFILL ® 100 U/ml solution for injection in cartridge. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of the solution contains 100 U of insulin aspart (equivalent to 3.5 mg). 1 cartridge contains 3 ml equivalent to 300 U. Insulin aspart is produced by recombinant DNA technology in _Saccharomyces cerevisiae._ PHARMACEUTICAL FORM Clear, colourless, aqueous solution for injection in cartridge. Penfill ® . THERAPEUTIC INDICATIONS Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. POSOLOGY NovoRapid ® is a rapid-acting insulin analogue. NovoRapid ® dosage is individual and determined in accordance with the needs of the patient. It should normally be used in combination with intermediate- acting or long-acting insulin given at least once a day. Blood glucose monitoring and insulin dose adjustment are recommended to achieve optimal glycaemic control. The individual insulin requirement in adults and children is usually between 0.5 and 1.0 U/kg/day. In a basal-bolus treatment regimen, 50 - 70% of this requirement may be provided by NovoRapid ® and the remainder by intermediate-acting or long-acting insulin. Adjustment of dosage may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness. NovoRapid ® has a faster onset and a shorter duration of action than soluble human insulin. Due to the faster onset of action, NovoRapid ® should generally be given immediately before a meal. When necessary NovoRapid ® can be given soon after a meal. Due to the shorter duration, NovoRapid ® has a lower risk of causing nocturnal hypoglycaemic episodes. SPECIAL POPULATIONS As with all insulin products, in elderly patients and patients with renal or hepatic impairment, glucose monitoring should be intensified and the insulin aspart dosage adjusted on an i Lesen Sie das vollständige Dokument
1 NOVORAPID ® Penfill ® 100 U/ml solution for injection in cartridge. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of the solution contains 100 U of insulin aspart* (equivalent to 3.5 mg). 1 cartridge contains 3 ml equivalent to 300 U. *Insulin aspart is produced by recombinant DNA technology in _Saccharomyces cerevisiae._ PHARMACEUTICAL FORM Clear, colourless, aqueous solution for injection in cartridge. Penfill ® . THERAPEUTIC INDICATIONS Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. POSOLOGY NovoRapid ® is a rapid-acting insulin analogue. NovoRapid ® dosage is individual and determined in accordance with the needs of the patient. It should normally be used in combination with intermediate- acting or long-acting insulin given at least once a day. Blood glucose monitoring and insulin dose adjustment are recommended to achieve optimal glycaemic control. The individual insulin requirement in adults and children is usually between 0.5 and 1.0 U/kg/day. In a basal-bolus treatment regimen, 50–70% of this requirement may be provided by NovoRapid ® and the remainder by intermediate-acting or long-acting insulin. Adjustment of dosage may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness. NovoRapid ® has a faster onset and a shorter duration of action than soluble human insulin. Due to the faster onset of action, NovoRapid ® should generally be given immediately before a meal. When necessary NovoRapid ® can be given soon after a meal. Due to the shorter duration, NovoRapid ® has a lower risk of causing nocturnal hypoglycaemic episodes. SPECIAL POPULATIONS As with all insulin products, in elderly patients and patients with renal or hepatic impairment, glucose monitoring should be intensified and the insulin aspart dosage adjusted on an individual basis. PAEDIATRIC POPULATION NovoRapid ® can be used in children aged 2 year and above in preference to soluble human insulin when a rapid onset of actio Lesen Sie das vollständige Dokument